UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2015

Enumeral Biomedical Holdings, Inc.

(Exact name of registrant as specified in its charter)

(617) 945-9146

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On September 28, 2015, the Compensation Committee of the Board of Directors (the “Board”) of Enumeral Biomedical Holdings, Inc. (the “Company”) granted each of the named executive officers of the Company listed below the number of stock options set forth opposite each individual’s name to purchase shares of Common Stock of the Company, $0.001 par value per share (the “Common Stock”), under the Company’s 2014 Equity Incentive Plan, as amended (the “2014 Plan”), with an exercise price equal to $0.36 per share (which represents the Fair Market Value, as defined in the 2014 Plan, of a share of Common Stock on the date of grant), such option awards evidenced by an option agreement under the 2014 Plan between each executive and the Company (collectively, the “Agreements”). Pursuant to the terms of the Agreements, the options vest as follows: (a) 50% of the shares underlying the options vest and become exercisable in 48 consecutive monthly installments on the 28th day of each month, with the first installment on October 28, 2015; (b) 25% of the shares underlying the options shall vest and become exercisable, if at all, upon the Company entering into a collaboration agreement with either an academic institution or a corporate partner on terms acceptable to the Board; and (c) 25% of the shares underlying the options shall vest and become exercisable, if at all, upon the closing of an equity financing transaction on terms acceptable to the Board with gross proceeds to the Company in excess of a specified amount.

The foregoing summary of the Agreements does not purport to be complete and is qualified in its entirety by reference to the Agreements, copies of which will be subsequently filed as an exhibit to the Company’s Quarterly Report on Form 10-Q or an amendment to this Current Report on Form 8-K. The Company intends to seek confidential treatment for certain portions of the Agreements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.